ORGO
Organogenesis Holdings Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.71
+4.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 456.5M | 563.0M | 482.0M | 433.1M | 450.9M |
| Cost of Revenue | 148.0M | 137.5M | 115.7M | 106.5M | 105.0M |
| Gross Profit | 308.6M | 425.5M | 366.3M | 326.7M | 345.9M |
| Operating Expenses | |||||
| R&D Expense | 57.0M | 44.5M | 50.3M | 44.4M | 39.8M |
| SG&A Expense | 299.1M | 326.2M | 294.5M | 269.8M | 283.8M |
| General & Admin Expense | 54.0M | — | 290.7M | 264.5M | 279.0M |
| Selling & Marketing Expense | — | — | 3.8M | 5.2M | 4.8M |
| Other Expenses | (18.3M) | (1.1M) | 22.8M | — | — |
| Total Operating Expenses | 337.7M | 369.6M | 367.6M | 314.1M | 323.6M |
| Cost and Expenses | 485.7M | 507.2M | 483.3M | 420.6M | 428.6M |
| Operating Income (EBIT) | (29.1M) | 55.9M | (1.3M) | 12.5M | 22.3M |
| Non-Operating | |||||
| Interest Income | 1.0M | 2.3M | — | — | — |
| Interest Expense | — | — | 1.5M | 2.2M | 2.0M |
| Net Interest Income | 1.0M | 2.3M | (1.5M) | (2.2M) | (2.0M) |
| Other Non-Op Income/Expense | (5.6M) | (8.9M) | (1.5M) | (2.1M) | (2.0M) |
| Non-Operating Income (excl Interest) | 5.6M | 8.9M | (20.0K) | (57.0K) | 13.0K |
| EBT (Pre-Tax Income) | (34.8M) | 47.0M | (2.8M) | 10.4M | 20.3M |
| Income Tax Expense | 52.4M | 9.9M | (3.7M) | 5.4M | 4.8M |
| Bottom Line | |||||
| Net Income | (90.2M) | 37.0M | 861.0K | 4.9M | 15.5M |
| Earnings from Cont. Ops | (87.2M) | 37.0M | 861.0K | 4.9M | 15.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (105.9M) | 20.0M | (937.0K) | 4.9M | 15.5M |
| Per Share | |||||
| Basic EPS | ($0.82) | $0.16 | ($0.01) | $0.04 | $0.12 |
| Diluted EPS | ($0.83) | $0.15 | ($0.01) | $0.04 | $0.12 |
| Revenue Per Share | $3.55 | $4.44 | $3.66 | $3.30 | $3.47 |
| Shares | |||||
| Basic Shares Outstanding | 128.7M | 126.7M | 131.7M | 131.2M | 130.1M |
| Diluted Shares Outstanding | 128.7M | 130.2M | 131.7M | 132.7M | 132.4M |
| Profitability Metrics | |||||
| EBITDA | (4.7M) | 73.9M | 15.8M | 36.0M | 40.3M |
| D&A | 30.0M | 26.9M | 17.0M | 23.4M | 18.0M |
| EBIT | (34.8M) | 47.0M | (1.3M) | 12.6M | 22.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026